Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Tecan Group (0QLN) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Tecan Group £57.38, price £232, upside -75.3%, quality 62 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? Yes
- Add to watchlist
TG
Broad data
Sep 24, 2026
Tecan Group
0QLN · LSEStretched ValuationStrong overvaluation with only moderate quality.
!Fair value £57.38 · Strongly overvalued (−75.3%)
✓Quality 62/100
!Weak Growth (revenue 5y +3.8 %/yr)
!Loss-making · -12.5% net margin (TTM)
✓Low debt · generates free cash flow
✓1.3% dividend yield · Well covered
!Narrow moat 21/100
Watch Tecan Group for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range £111.59 – £597.36 · fair‑value band £42.13 – £72.62 · the £232.20 price screens above the £57.38 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Company profile
Tecan Group AG provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally. It operates in two segments: Life Sciences Business and Partnering Business.
Show more
Tecan Group AG provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally. It operates in two segments: Life Sciences Business and Partnering Business. The company offers liquid handling and automation, microplate readers and washers, software, consumables, sequencing reagents, immunoassays and antibodies, and Tecan Labwerx, an end-to-end automation solution. It also provides PARAMIT, a contract design and manufacturing service. Tecan Group AG has a strategic collaboration with NVIDIA Corporation to develop AI-enabled platform for data-driven laboratories to help discoveries and lab productivity. The company was founded in 1980 and is headquartered in Männedorf, Switzerland.
Stock analysis
Tecan Group (0QLN) currently trades at £232.20, while our model-based Fair Value estimate is £57.38, 75.3% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of £147.96 per share, and 0 of the 15 models we run sit above the £232.20 price.
Bear case: the Dividend Discount group reads lowest at £38.11, and 15 of the 15 models stay below the price. Evidence for this calculation is high.
Scenario range: £42.13 (bear) to £72.62 (bull), the price of £232.20 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 62/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Tecan Group reported revenue of £882M in FY2025 versus £947M in FY2021, a compound −1.7%/yr. Reported net income was −£111M in FY2025.
Key figures
Market cap £1.4B · P/E ratio 0.2 · P/S ratio 1.58 · EPS (TTM) £9.88 · Dividend yield 1.3% · Net margin −12.5% · Return on equity −8.6% · Return on assets (EBIT) 5.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 1% below its 52-week high and 108% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −37% fair-value upside, at −75%, 0QLN screens richer than that median.
Fair Value models
Bear £42.13
Fair Value £57.38
Bull £72.62
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (£5.20 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
£118.97
£162.90
£220.46
79
Growth DCF
£119.89
£158.43
£205.98
77
EPV
£37.23
£40.27
£42.81
74
All 15 models by family
DCF Models
FCF DCF
£118.97
£162.90
£220.46
79
5Y Revenue Exit
£75.33
£95.47
£119.31
72
5Y EBITDA Exit
£105.36
£150.93
£202.65
73
10Y Revenue Exit
£91.65
£113.02
£138.65
66
10Y EBITDA Exit
£109.89
£147.96
£196.07
67
Earnings-Based
EPV
£37.23
£40.27
£42.81
74
Dividend Discount
Gordon GGM
£25.12
£45.27
£62.33
66
DDM Multi-Stage
£25.12
£38.11
£48.36
65
Multiples
EV/EBIT
£60.66
£75.90
£91.14
66
EV/EBITDA
£107.05
£137.76
£168.46
67
EV/Revenue
£47.57
£61.56
£75.54
54
Asset-Based
NCAV (Graham)
£48.96
£65.61
£97.92
54
Growth DCF
Growth DCF
£119.89
£158.43
£205.98
77
Rev-Margin DCF
£75.33
£97.26
£122.79
72
Economic Profit
ROIC Compounder
£37.23
£40.27
£42.81
70
Notify me when 0QLN reaches fair value
Put 0QLN on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
62/100
Of which business quality 63 · Market factors (momentum, volatility) 78
Profitability
12
Margins and returns on capital today
Quality Growth
36
Are margins and returns improving?
Cashflow
71
Earnings quality: real cash, not paper profit
Fin. Strength
85
Balance sheet, leverage, solvency risk
Investment
100
Disciplined investing over empire-building
Low Volatility
52
Calm price path (market factor)
Momentum
87
Price trend over the last 3–12 months (market factor)
52W Momentum
95
Distance to the 52-week high (market factor)
Net Issuance
88
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
37/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−5.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.8%
Start year 2020 (pandemic). Over 10 years: +7.2% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
16.8% (2020) → 4.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+16.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+3.7%
Yearly sales growth analysts expect, extended to five years.
After inflation (UK: IMF forecast 2.3% a year to 2030, 3.3% from 2016 to 2025) that is about +13.4% a year for the price and +1.3% for the forecasts.
Forecast 2026 (sales)+0.1%
Forecast 2027 (sales)+5.2%
Projected 2028 (sales)+4.8%
Projected 2029 (sales)+4.4%
Projected 2030 (sales)+4.0%
0QLN screens overvalued: fair value 75% below the price. Compare with Intuitive Surgical, Inc →
Compare Tecan Group with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 185 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: UK Stocks
- Valuation of the UK market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $406.63 | $348.72 | −14% |
| EssilorLuxottica Société anonyme EL | €144.60 | €159.06 | +10% |
| Becton, Dickinson and Company BDX | $178.07 | $104.73 | −41% |
| Medline Inc MDLN | $34.70 | $29.06 | −16% |
| Alcon Inc ALC | $63.94 | $40.13 | −37% |
| West Pharmaceutical Services, Inc WST | $375.65 | $137.81 | −63% |
| Sartorius Stedim Biotech S.A DIM | €208.20 | €54.82 | −74% |
| Straumann Holding STMN | CHF 89.80 | CHF 45.50 | −49% |
| Sartorius Aktiengesellschaft SRT | €206.50 | €42.05 | −80% |
| Solventum Corporation SOLV | $89.50 | $134.36 | +50% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Tecan Group (0QLN) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of £57.38 versus a price of £232.20, about −75% upside (overvalued).
What is the fair value of 0QLN?
Our model-based fair value for Tecan Group is £57.38 (as of Sep 24, 2026), built from audited fundamentals. The current price: £232.20.
What is the quality score of 0QLN?
Tecan Group has a Quality Score of 62/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Tecan Group (0QLN)?
Our model-based price target is the fair value of £57.38 (as of Sep 24, 2026) from 15 valuation models. Cautious scenario £42.13, optimistic scenario £72.62. It is a calculation from audited fundamentals, not an analyst target.
What is the Tecan Group stock forecast for 2026?
Our models put fair value at £57.38, about −75% upside versus a price of £232.20 (overvalued). Cautious scenario £42.13, optimistic scenario £72.62. The calculation is refreshed regularly with new filings.
What is the revenue of Tecan Group (0QLN)?
Tecan Group reported trailing-twelve-month revenue of about £882M (latest available figure, as of Sep 24, 2026).
Does Tecan Group pay a dividend?
Tecan Group currently shows a dividend yield of about 1.29% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Tecan Group (0QLN)?
For today's price to be fair in a discounted-cash-flow model, Tecan Group would have to grow free cash flow by +16.0 % per year for five years (discount rate 12.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +3.8 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 0QLN use?
Our models discount Tecan Group at 12.0 %: a base by market capitalisation (small), damped by beta 1.07, country premium for United Kingdom. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Tecan Group that is +16.0 % per year a year over ten years, using the same discount rate (12.0 %) and the same formula as our fair value.
How much growth has Tecan Group (0QLN) delivered so far?
Over the past 5 years revenue at Tecan Group grew +3.8 % a year. The price currently implies +16.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Tecan Group (0QLN) growing?
The median revenue growth in the sector is +7.0 % a year. That is the yardstick for the growth priced into Tecan Group (+16.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Tecan Group (0QLN)?
The free-cash-flow yield on the price is 4.23 %: that much free cash flow Tecan Group produces per unit of market value. When it exceeds the discount rate of our models (12.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Tecan Group (0QLN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Tecan Group it is £57.38 per share (as of Sep 24, 2026), against a price of £232.20. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Tecan Group stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0QLN trades above its calculated fair value: price £232.20, fair value £57.38, a gap of about −75% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0QLN?
No. The price is what the market pays today (£232.20); the fair value is what the company's own numbers justify (£57.38). For Tecan Group the two are £174.82 per share apart. That gap is exactly why we show both numbers side by side.
How much is Tecan Group worth?
The market values Tecan Group at about £1.4B (market capitalisation, as of Sep 24, 2026). Per share that is £232.20; our models calculate a fair value of £57.38 per share.
What do the bullish and bearish scenarios say about 0QLN?
Our models span a range for Tecan Group: cautious scenario £42.13, base £57.38, optimistic £72.62 per share (as of Sep 24, 2026, price £232.20). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 0QLN?
Tecan Group trades at a price-to-earnings ratio of 0.2 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of £57.38 is built from several models across several years. Other multiples: P/B 1.6, P/S 2.1, EV/EBITDA 21.1.
How solid is the balance sheet of Tecan Group (0QLN)?
Balance-sheet figures for Tecan Group (as of Sep 24, 2026): return on equity −8.6%, debt of 0.00 per unit of equity. They feed the Quality Score of 62/100, which measures business quality independently of the share price.
How far is 0QLN from its 52-week high?
Tecan Group trades at £232.20, about 1% below its 52-week high of £233.80 and 108% above the low of £111.59 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of £57.38 is for.
Which stocks are comparable to Tecan Group?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Tecan Group stock attractive at the current price?
The data as of Sep 24, 2026: price £232.20, calculated fair value £57.38 (−75%), Quality Score 62/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0QLN calculated?
We run Tecan Group through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of £57.38, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Tecan Group itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Tecan Group (0QLN)?
The closing price on Oct 2, 2026 was £232.20. Our model-based fair value is £57.38, about −75% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Tecan Group right now?
The price sits above even our optimistic bull case (£72.62). The favourable scenario is already priced in. Solid but not exceptional quality (62/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of Tecan Group (0QLN) come from?
Earnings per share at Tecan Group grew +7.0 % a year from 2014 to 2025. Broken into its drivers: revenue per share +8.6 %, EBIT margin −3.6 %, tax rate +1.3 %, residual (interest, one-offs) +0.9 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Tecan Group
How large is the market capitalisation of Tecan Group (0QLN)?
The market capitalisation of Tecan Group is £1.4B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Tecan Group (0QLN)?
The price-to-sales ratio of Tecan Group is 1.58 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Tecan Group (0QLN)?
Earnings per share at Tecan Group are £9.88 (price ÷ EPS = P/E 0.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Tecan Group (0QLN)?
The dividend yield of Tecan Group is 1.3% (payout 30.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Tecan Group (0QLN)?
The net margin of Tecan Group is −12.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Tecan Group (0QLN)?
The return on equity (ROE) of Tecan Group is −8.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Tecan Group (0QLN)?
On an EBIT basis the return on assets of Tecan Group is 5.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Tecan Group (0QLN)?
The operating margin of Tecan Group is 4.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Tecan Group (0QLN)?
Revenue at Tecan Group is growing −5.2% versus a year earlier (3y avg −8.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Tecan Group (0QLN)?
Earnings per share at Tecan Group are growing −19.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Tecan Group (0QLN) carry?
The net debt of Tecan Group is £42.2M (fiscal year 2025, ≈ 0.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Tecan Group in the live analysis
One click puts Tecan Group on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.